A Phase 3 interventional study of Dapagliflozin 10 mg and Placebo tablet in Diabetes Mellitus, Non-Insulin-Dependent and High Risk for Cardiovascular Event, sponsored by AstraZeneca. Completed at 807 sites in 34 countries. Open to participants aged 40 Years to 130 Years. Per ClinicalTrials.gov, last updated 2019-12-26.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 — 15 open to participants now, 19 under way, 5 of them phase 3. dapagliflozin · Diabetes Mellitus, Type 2.
Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, this one is the 2nd largest by enrollment, is the only one that started in 2013, is one of 47 in phase 3, and was the 46th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →15 of the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, China and 10 more countries
Ages 18+
AstraZeneca · Sites in United States, Argentina, Brazil and 21 more countries
Ages 18+
Junjie Yang · Sites in China
Ages 18–78
Herlev and Gentofte Hospital · Sites in Denmark
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
By country, each count listing its studies:
dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 40 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
180 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 21 · Phase 3 53 · Phase 4 77
First in 2005; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17,190 is above the median of 80 across 8,365 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 82 across the 180 interventional studies. Of the 136 that completed or were terminated, 68 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
82 of 180 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
345 studies in Diabetes Mellitus, Type 2 by AstraZeneca: 13 open now, 15 under way, 9 of them phase 3. Of 325 finished, 149 (46%) have results posted.
Among the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, this one is the 3rd largest by enrollment of the 280 interventional ones that give a count, is one of 7 that started in 2013, is one of 119 in phase 3, and was the 220th registered.
AstraZeneca’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
6 of the studies testing dapagliflozin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07311551Bhavya Bhavya, MDA Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI) | 2026-12 |
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
| NCT07614230Junjie YangSGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes | 2027-06-01 |
| NCT07891234Sherihan AboElyazed Mohamed KhalilEffect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance | 2027-10-01 |
| NCT05938712University Health Network, TorontoThe Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients | 2027-10-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Among AstraZeneca’s 345 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This study is being carried out to determine the effect of dapagliflozin on cardiovacular outcomes when added to current background therapy in patients with type 2 diabetes with either established cardiovacular disease or cardiovascular risk factors.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dapagliflozin + standard of care therapy for Type 2 Diabetes and for co-morbidities and cardiovascular risk factors
Drug: Dapagliflozin 10 mg
Placebo + standard of care therapy for Type 2 Diabetes and for co-morbidities and cardiovascular risk factors
Drug: Placebo tablet
Oral dose (od)
Oral dose (od)
Subjects Included in the Composite Endpoint of CV Death, MI or Ischemic Stroke
Safety and co-primary efficacy
Time frame: up to 5.2 years
Subjects Included in the Composite Endpoint of CV Death or Hospitalization Due to Heart Failure.
Co-primary efficacy
Time frame: up to 5.2 years
Subjects Included in the Renal Composite Endpoint: Confirmed Sustained ≥40% Decrease in eGFR to eGFR <60 ml/Min/1.73m2 and/or ESRD and/or Renal or CV Death.
Secondary
Time frame: up to 5.2 years
Subjects Included in the Endpoint of All-cause Mortality.
Secondary
Time frame: up to 5.2 years
| Milestone | Dapa 10 mg | Placebo |
|---|---|---|
| Started | 8582 | 8578 |
| Completed | 8473 | 8433 |
| Not completed | 109 | 145 |
| Withdrew: Withdrawal by subject | 97 | 127 |
| Withdrew: Lost to follow-up | 12 | 18 |
Safety and co-primary efficacy
| Participants | Dapa 10 mg | Placebo |
|---|---|---|
| Number of patients with an event | 756 | 803 |
Co-primary efficacy
| Participants | Dapa 10 mg | Placebo |
|---|---|---|
| Number of patients with an event | 417 | 496 |
Secondary
| Participants | Dapa 10 mg | Placebo |
|---|---|---|
| Number of patients with an event | 370 | 480 |
Secondary
| Participants | Dapa 10 mg | Placebo |
|---|---|---|
| Number of patients with an event | 529 | 570 |
Collected over up to 5.2 years. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dapa 10 mg | 529/8,582 (6.2%) | 3,205/8,574 (37.4%) | 268/8,574 (3.1%) |
| Placebo | 570/8,578 (6.6%) | 3,418/8,569 (39.9%) | 342/8,569 (4%) |
| Event | Dapa 10 mg | Placebo |
|---|---|---|
| Angina unstableCardiac disorders | 271/8574 | 269/8569 |
| Acute myocardial infarctionCardiac disorders | 265/8574 | 233/8569 |
| PneumoniaInfections and infestations | 194/8574 | 219/8569 |
| Cardiac failureCardiac disorders | 147/8574 | 188/8569 |
| Angina pectorisCardiac disorders | 154/8574 | 159/8569 |
| Cardiac failure congestiveCardiac disorders | 121/8574 | 147/8569 |
| Atrial fibrillationCardiac disorders | 117/8574 | 139/8569 |
| Acute kidney injuryRenal and urinary disorders | 94/8574 | 127/8569 |
| Myocardial infarctionCardiac disorders | 96/8574 | 108/8569 |
| Non-cardiac chest painGeneral disorders | 93/8574 | 107/8569 |
| Event | Dapa 10 mg | Placebo |
|---|---|---|
| Renal impairmentRenal and urinary disorders | 121/8574 | 146/8569 |
| Acute kidney injuryRenal and urinary disorders | 82/8574 | 112/8569 |
| Chronic kidney diseaseRenal and urinary disorders | 77/8574 | 104/8569 |
| Age, Continuous(years) | Dapa 10 mg | Placebo | Total |
|---|---|---|---|
| Mean | 63.9 ± 6.8 | 64.0 ± 6.8 | 63.9 ± 6.8 |
| Age, Customized(Participants) | Dapa 10 mg | Placebo | Total |
|---|---|---|---|
| <65 years | 4631 | 4622 | 9253 |
| >=65 years | 3951 | 3956 | 7907 |
| Age, Customized(Participants) | Dapa 10 mg | Placebo | Total |
|---|---|---|---|
| <75 years | 8044 | 8020 | 16064 |
| >=75 years | 538 | 558 | 1096 |
| Sex: Female, Male(Participants) | Dapa 10 mg | Placebo | Total |
|---|---|---|---|
| Female | 3171 | 3251 | 6422 |
| Male | 5411 | 5327 | 10738 |
| Ethnicity (NIH/OMB)(Participants) | Dapa 10 mg | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 1298 | 1270 | 2568 |
| Not Hispanic or Latino | 7284 | 7308 | 14592 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Dapa 10 mg | Placebo | Total |
|---|---|---|---|
| White | 6843 | 6810 | 13653 |
| Black or African American | 295 | 308 | 603 |
| Asian | 1148 | 1155 | 2303 |
| American Indian or Alaska Native | 52 | 52 | 104 |
| Native Hawaiian or other Pacific Islander | 9 | 13 | 22 |
| Other | 235 | 240 | 475 |
| Baseline CV risk category(Participants) | Dapa 10 mg | Placebo | Total |
|---|---|---|---|
| Established CV disease | 3474 | 3500 | 6974 |
| Multiple risk factors for CV events | 5108 | 5078 | 10186 |
Showing the first 100 of 807 sites across 34 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2013 to primary completion in Sep 2018, 64 months.
Results were first posted in Dec 2019, 1 year 3 months after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 64 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dapagliflozin